EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

CRISPR delivery with extracellular vesicles: Promises and challenges

Anne Højberg Berggreen, Julie Lund Petersen, Lin Lin, Karim Benabdellah iD, Yonglun Luo iD

Journal of Extracellular Biology · 2023-09 · 2 (9)

DOI: 10.1002/jex2.111 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Extracellular Biology, online erschienen am 21.09.2023. Verfasst von Anne Højberg Berggreen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine Aarhus University Aarhus Denmark. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Cooperation in Science and Technology, Innovationsfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CRISPR gene editing tool holds great potential for curing genetic disorders. However, the safe, efficient, and specific delivery of the CRISPR/Cas9 components into cells and tissues remains a challenge. While many currently available delivery methods achieve high levels of gene editing effects in vivo, they often result in genotoxicity and immunogenicity. Extracellular vesicles (EVs), which are cell‐derived lipid nanoparticles, are capable of transferring protein and nucleic acid cargoes between cells, making them a promising endogenous alternative to synthetic delivery methods. This review provides a comprehensive analysis of the currently available strategies for EV‐mediated delivery of CRISPR/Cas9. These strategies include cell‐based, passive loading obtained by overexpression of CRISPR/Cas9, active loading involving protein or RNA dimerization, and loading into already purified EVs. All these approaches suggest that EV‐based CRISPR/Cas9 delivery is useful for achieving both in vitro and in vivo gene editing. Despite that, substantial variations in cellular uptake and gene editing efficiencies indicate that further improvement and standardization are required for the therapeutic use of EVs as a CRISPR/Cas9 delivery vehicle. These improvements include, but is not limited to, the high‐yield purification of EVs, increased loading and release efficiencies, as well as improved tissue‐ or cell‐specific targeting specificities.

Schlagwörter

Stichwörter der Autor:innen

CRISPRCas9LNPexosomeextracellular vesiclesgene editinggene therapy

Autor:innen und Institutionen

  • Department of Biomedicine Aarhus University Aarhus Denmark.
  • Steno Diabetes Center Aarhus Aarhus University Hospital Aarhus Denmark.
  • Pfizer-Universidad de Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO) Granada Spain.
  • Lars Bolund Institute of Regenerative Medicine, Qingdao Europe Advanced Institute for Life Sciences BGI-Research Qingdao China.
  • Lars Bolund Institute of Regenerative Medicine, HIM-BGI Omics Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences Zhejiang Hangzhou China.

ORCID-Profile: Karim Benabdellah, Yonglun Luo

Förderung

  • European Cooperation in Science and Technology
  • Innovationsfonden

Zitieren

APA

Berggreen, A. H., Petersen, J. L., Lin, L., Benabdellah, K., & Luo, Y. (2023). CRISPR delivery with extracellular vesicles: Promises and challenges. Journal of Extracellular Biology, 2(9). https://doi.org/10.1002/jex2.111

Vancouver

Berggreen AH, Petersen JL, Lin L, Benabdellah K, Luo Y. CRISPR delivery with extracellular vesicles: Promises and challenges. Journal of Extracellular Biology. 2023;2(9). doi:10.1002/jex2.111

BibTeX
@article{Berggreen2023,
  author = {Berggreen, Anne Højberg and Petersen, Julie Lund and Lin, Lin and Benabdellah, Karim and Luo, Yonglun},
  title = {CRISPR delivery with extracellular vesicles: Promises and challenges},
  journal = {Journal of Extracellular Biology},
  year = {2023},
  volume = {2},
  number = {9},
  doi = {10.1002/jex2.111}
}
Kostenlos starten →